Abstract 2783
Background
Individual Care plans should be a co-creation between the patient and the health care provider, and should be updated by the contact nurse (CN) that is the patients’ main point of contact. Until recently the individual care plans for patients with Head & Neck cancer (H&N) in our region constituted of extensive written information in a ring binder and in addition a treatment plan from the medical records were printed and given to the patient. This quality improvement project aims to implement a digital and interactive version of the care plan, with a greater possibility to tailor information and increased availability. The implementation process contained of both the introduction of the digital tool (the care plan) and also new work processes for the nurses.
Methods
We followed the Plan Do Study Act approach. A clinical nurse leader together with the designer of the and an IT-technician worked together with the preparations (education, testing and risk assessment). All patients with H&N cancer could choose a standard care plan or the new digital format. The digital care plan was prepared by the CN. A person-centered approach was adopted for the digital care plans, with mandatory questions at the first visit with the CN; “What is important to you? - What is important that I know about you?”.
Results
30 % of chose the digital version of the individual care plan (n = 45) (patients were asked to choose either printed or digital). Patients and nurses were asked to give feedback on the content, usefulness and to suggest improvements. The first evaluation from the patients suggests improved patient participation and satisfaction. The CN stated that the digital care plan had advantages such as less time consuming, improved communication with the patients and supporting person-centered care. The patients can interact with the CN and may also use different symptom assessment scales and were involved during the whole implementation phase.
Conclusions
There is a potential for increased use of screening tools and systematic assessment of symptoms with the digital version of the IWCP. The mandatory question gave important information to the CN to consider. A designated nurse leader involved in the process is important during the implementation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Regional Cancer Center Stockholm Gotland.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5650 - Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis.
Presenter: Sarah Sasson
Session: Poster Display session 3
Resources:
Abstract
5944 - Significance of severe immune-related adverse effects (irAE) on patients with advanced tumors treated with immune checkpoint inhibitors being admitted for secondary toxicity: Clinical relevance and next steps
Presenter: Leyre Zubiri
Session: Poster Display session 3
Resources:
Abstract
5989 - Implementation of a dedicated immuno-oncology toxicity service reduces the acute impact of immune-related adverse events
Presenter: Anna Olsson-Brown
Session: Poster Display session 3
Resources:
Abstract
3267 - Cardiotoxic and pro-inflammatory effects induced by the association of immune checkpoint inhibitor Pembrolizumab and Trastuzumab in preclinical models
Presenter: Nicola Maurea
Session: Poster Display session 3
Resources:
Abstract
3417 - Interstitial lung disease associated with immune-checkpoint inhibitors in malignant diseases
Presenter: Akira Yamagata
Session: Poster Display session 3
Resources:
Abstract
2071 - A Phase 1 Study of Intraperitoneal MCY-M11 Anti-Mesothelin CAR for Women with Platinum Resistant High Grade Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube, or Subjects with Peritoneal Mesothelioma with Recurrence after Prior Chemotherapy
Presenter: Christina Annunziata
Session: Poster Display session 3
Resources:
Abstract
4935 - Trial in progress: First-in-human study of a novel anti-NY-ESO-1–anti-CD3, TCR-based bispecific (IMCnyeso) as monotherapy in NY-ESO-1/LAGE-1A-positive advanced solid tumors (IMCnyeso-101)
Presenter: Juanita Lopez
Session: Poster Display session 3
Resources:
Abstract
5613 - Nimotuzumab-Cisplatin-Radiation versus Cisplatin-Radiation in HPV negative oropharyngeal cancer
Presenter: Kumar Prabhash
Session: Poster Display session 3
Resources:
Abstract
2576 - Interim analysis of a single arm phase 2 study of adjuvant nivolumab after salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy.
Presenter: Trisha Wise-draper
Session: Poster Display session 3
Resources:
Abstract
4758 - A Phase I Study of the CDK4/6 Inhibitor, Palbociclib in combination with Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN); A Result of Dose Escalation Cohort
Presenter: Nuttapong Ngamphaiboon
Session: Poster Display session 3
Resources:
Abstract